Pacific Biosciences | GenomeWeb

Pacific Biosciences

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.

The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market. 

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

PacBio released an upgrade to its Sequel system last month that improves loading efficiency, which has increased average throughput and read length. 

PacBio's product revenues increased due to sales of its Sequel system. The company also alleged that Oxford Nanopore's products infringe on a patent it holds. 

This Week in Nature

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Researchers from Pacific Biosciences and elsewhere tested their approach on Arabidopsis thaliana before applying it to wine grape and coral fungus genomes.

The researchers believe using PacBio's Sequel systems will allow them to create high-quality reference genome assemblies.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.